We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Cell Biologists Find That Certain Mitochondrial Diseases Stem from Coenzyme Q10 Depletion

By LabMedica International staff writers
Posted on 25 Feb 2015
A team of German cell biologists has linked the development of certain mitochondrial-linked diseases to depletion of the organelles' pool of coenzyme Q10 brought about by mutation in the MFN2 gene, which encodes the fusion protein mitofusin 2.

Despite the established role of mitofusins (Mfn1 and Mfn2) in mitochondrial fusion, only Mfn2 had been associated with metabolic and neurodegenerative diseases, which suggests that this protein is needed to maintain mitochondrial energy metabolism. More...
Mice lacking the MFN1 gene, which encodes mitofusin 1, seem perfectly healthy, but MFN2-deficient mice die soon after birth. Furthermore, mutations in the MFN2 gene cause human diseases, including the peripheral neuropathy Charcot-Marie-Tooth type 2A. The molecular basis for the mitochondrial dysfunction encountered in the absence of Mfn2 has not been explained.

In the current study, investigators at the Max Planck Institute for Biology of Ageing (Cologne, Germany) worked with cultures of mouse heart muscle cells lacking the MFN2 gene.

They reported in the February 16, 2015, online edition of the Journal of Cell Biology that energy metabolism in the cells was impaired compared to that of healthy heart cells or of heart cells that lacked only Mfn1. The energy metabolic process in the Mfn2-deficient cells was found to have been disrupted by reduced levels of coenzyme Q, a key component of the mitochondrial respiratory chain that generates cellular energy in the form of ATP.

The reduced respiratory chain function in the mitochondria of cells lacking Mfn2 could be partially restored by supplementation with coenzyme Q10, which suggested a possible therapeutic strategy for patients with diseases caused by mutations in the MFN2 gene.

Related Links:

Max Planck Institute for Biology of Ageing



Gold Member
Neonatal Heel Incision Device
Tenderfoot
Online QC Software
Acusera 24•7
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.